Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M106,389Revenue (TTM) $M36,959Net Margin (%)0.1Altman Z-Score1.2
Enterprise Value $M127,724EPS (TTM) $0.0Operating Margin %5.3Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.6Pre-tax Margin (%)2.8Higher ROA y-yN
Price/Book14010-y EBITDA Growth Rate %1.7Quick Ratio0.6Cash flow > EarningsY
Price/Sales3.25-y EBITDA Growth Rate %7.4Current Ratio0.9Lower Leverage y-yY
Price/Free Cash Flow53.7y-y EBITDA Growth Rate %-78.8ROA % (ttm)0.1Higher Current Ratio y-yN
Dividend Yield %5.1PEG--ROE % (ttm)0.8Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M2,436ROIC % (ttm)3.7Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKKahn Brothers 2016-06-30 Add2.08%$40.04 - $43.47
($42.12)
$ 43.674%Add 188.24%380,335
GSKNWQ Managers 2016-06-30 Add1.17%$40.04 - $43.47
($42.12)
$ 43.674%Add 316.61%2,075,187
GSKCharles Brandes 2016-06-30 Reduce-0.14%$40.04 - $43.47
($42.12)
$ 43.674%Reduce -5.59%4,224,506
GSKHOTCHKIS & WILEY 2016-06-30 Reduce-0.08%$40.04 - $43.47
($42.12)
$ 43.674%Reduce -5.34%8,439,389
GSKJoel Greenblatt 2016-06-30 Reduce-0.01%$40.04 - $43.47
($42.12)
$ 43.674%Reduce -49.63%25,857
GSKKen Fisher 2016-06-30 Add0.01%$40.04 - $43.47
($42.12)
$ 43.674%Add 0.63%11,730,875
GSKJohn Rogers 2016-06-30 Add0.01%$40.04 - $43.47
($42.12)
$ 43.674%Add 1.57%1,607,697
GSKTweedy Browne 2016-06-30 Add$40.04 - $43.47
($42.12)
$ 43.674%Add 0.36%116,491
GSKDodge & Cox 2016-06-30 Reduce$40.04 - $43.47
($42.12)
$ 43.674%Reduce -45.53%44,262
GSKHOTCHKIS & WILEY 2016-03-31 Reduce-0.52%$38.54 - $42.05
($39.84)
$ 43.6710%Reduce -26.34%8,915,323
GSKKahn Brothers 2016-03-31 Add0.36%$38.54 - $42.05
($39.84)
$ 43.6710%Add 55.97%131,950
GSKCharles Brandes 2016-03-31 Add0.1%$38.54 - $42.05
($39.84)
$ 43.6710%Add 3.98%4,474,409
GSKJohn Rogers 2016-03-31 Add0.05%$38.54 - $42.05
($39.84)
$ 43.6710%Add 7.17%1,582,913
GSKTweedy Browne 2016-03-31 Reduce-0.02%$38.54 - $42.05
($39.84)
$ 43.6710%Reduce -12.81%116,070
GSKNWQ Managers 2016-03-31 Add0.02%$38.54 - $42.05
($39.84)
$ 43.6710%Add 6.02%498,115
GSKKen Fisher 2016-03-31 Add0.01%$38.54 - $42.05
($39.84)
$ 43.6710%Add 1.09%11,657,855
GSKJoel Greenblatt 2016-03-31 Reduce$38.54 - $42.05
($39.84)
$ 43.6710%Reduce -1.24%51,331
GSKBarrow, Hanley, Mewhinney & Strauss 2016-03-31 Add$38.54 - $42.05
($39.84)
$ 43.6710%Add 1.12%251,800
GSKDodge & Cox 2016-03-31 Reduce$38.54 - $42.05
($39.84)
$ 43.6710%Reduce -27.95%81,262
GSKCharles Brandes 2015-12-31 Reduce-0.21%$39.1 - $43.53
($40.81)
$ 43.677%Reduce -7.92%4,303,030
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$2298.5view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.14106.58view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29725.52view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12263.92view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14211.93view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12263.92view

Press Releases about GSK :

Quarterly/Annual Reports about GSK:

    News about GSK:

    Articles On GuruFocus.com
    Ariel Funds Comments on GlaxoSmithKline plc Sep 28 2016 
    John Rogers' Ariel Global Fund 2nd Quarter Commentary Sep 28 2016 
    Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap Sep 19 2016 
    Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
    GlaxoSmithKline's Dividend Health Aug 09 2016 
    Tweedy Browne 2nd Quarter Shareholder Letter Aug 01 2016 
    GlaxoSmithKline’s Sideways Dance May Pay Off in the Long Run Jul 22 2016 
    Why Berkshire Hathaway Dumped Johnson & Johnson Jul 19 2016 
    Andreas Halvorsen's Viking Global Gets Control of Stakes in 2 Companies for Backing Hot Biotech Jul 14 2016 
    Investing in Big Pharma: Pointers on Pfizer Jul 14 2016 

    More From Other Websites
    Ariel Funds Comments on GlaxoSmithKline plc Sep 28 2016
    John Rogers' Ariel Global Fund 2nd Quarter Commentary Sep 28 2016
    Glaxo to Sell Rest of Stake in South African Drugmaker Aspen Sep 28 2016
    GlaxoSmithKline Vaccines for Malaria, Zika Make It a Likely Winner Sep 28 2016
    The Zacks Analyst Blog Highlights: General Electric, GlaxoSmithKline and McDonald Sep 28 2016
    Battle of the Pharmaceutical Bigwigs: GlaxoSmithKline vs. Pfizer Sep 28 2016
    6:06 am GlaxoSmithKline Consumer Healthcare Pte enters license agreement w/ Nutritional Growth... Sep 28 2016
    New Research Reports for GE, McDonald's & GSK Sep 27 2016
    France’s Essilor Said to Hire Glaxo’s Halper as Head of M&A Sep 26 2016
    Director/PDMR Shareholding Sep 26 2016
    The Internet of Medical Things: 6 Stocks in Focus Sep 26 2016
    Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S. Sep 26 2016
    5 Stocks to Sell Now Before It's Too Late Sep 24 2016
    GSK announces US regulatory submission for sirukumab in rheumatoid arthritis Sep 23 2016
    US Regulatory Submission for sirukumab in RA Sep 23 2016
    [$$] GSK's 'fiercely competitive' Emma Walmsley faces test of experience Sep 23 2016
    Coverage initiated on GlaxoSmithKline by Piper Jaffray Sep 23 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)